Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial
Robin Kate Kelley(UCSF Helen Diller Family Comprehensive Cancer Center), Ming‐Huang Chen(National Yang Ming Chiao Tung University), Li‐Yuan Bai(China Medical University), Uwe Pelzer(Humboldt-Universität zu Berlin), Robert Bordonaro, Irit Ben‐Aharon(Technion – Israel Institute of Technology), Kritiya Butthongkomvong, Susan E. Bates(The Nature Conservancy), Çağatay Arslan, Adam M. Burgoyne, Usha Malhotra(Unknown), Olga Barajas(Fundación Arturo López Pérez), Masato Ozaka(The Cancer Institute Hospital), Gustavo R. Alves(Universidade do Porto), Marcos Pedro Guedes Camandaroba, Eric Assénat, Nina Beri(NYU Langone Health), Joon Oh Park(Samsung Medical Center), Stephen L. Chan(Chinese University of Hong Kong), Makoto Ueno(Kanagawa Prefectural Hospital Organization), Heinz‐Josef Klümpen(University Medical Center Groningen), Jen‐Shi Chen(Linkou Chang Gung Memorial Hospital), Junji Furuse(Kanagawa Prefectural Hospital Organization), Sumitra Anand, Jamil Asselah, Giovanni Brandi(Hôpital Beaujon), Julien Edeline(Inserm), Marie‐Luise Berres, Richard S. Finn(University of California, Los Angeles), Stephen Begbie(Chinese University of Hong Kong), Juan W. Valle(Cancer Research UK Manchester Institute), Mehmet Akce(Medizinische Hochschule Hannover), Arndt Vogel(Princess Margaret Cancer Centre), Jean‐Frédéric Blanc, Mohamed Bouattour(Hôpital Beaujon), Yuxian Bai(Harbin Medical University), Thomas Yau(University of Hong Kong), Marcela Carballido, Changhoon Yoo(Ulsan College), Li Yu(Decision Sciences (United States)), Zhenggang Ren(Sun Yat-sen University), Inmaculada Alés Díaz, Ke Cao(UCSF Helen Diller Family Comprehensive Cancer Center), Chris Verslype(Universitair Ziekenhuis Leuven), Abby B. Siegel(Merck & Co., Inc., Rahway, NJ, USA (United States)), Ivan Borbath
Cited by 1,011
Related Papers
<i>MET</i> Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling
|Science|2007|4.5k
Palbociclib and Letrozole in Advanced Breast Cancer
|New England Journal of Medicine|2016|2.9k
FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer
|New England Journal of Medicine|2018|2.8k
Tremelimumab plus Durvalumab in Unresectable Hepatocellular Carcinoma
|NEJM Evidence|2022|1.4k